Smith Jason A, Fan Chun-Yang, Zou Chunlai, Bodenner Donald, Kokoska Mimi S
Otolaryngology, Surgical Services, and Department of Pathology, Central Arkansas Veterans Healthcare System, and Department of Otolaryngology, University of Arkansas for Medical Sciences, 4301 W Markham, Slot 543, Little Rock, AR 72205, USA.
Arch Otolaryngol Head Neck Surg. 2007 Oct;133(10):1006-11. doi: 10.1001/archotol.133.10.1006.
To determine the methylation status of gene promoter regions using methylation-specific polymerase chain reaction in genes encoding for thyrotropin receptor (TSHR), E-cadherin (ECAD), sodium iodide symporter protein (NIS-L), ataxia telangiectasia mutated (ATM), and death-associated protein kinase (DAPK) proteins and if methylation status correlates with patient variables, tumor factors, or outcome measures among patients with papillary thyroid carcinoma.
Database query and retrospective medical chart review for patients with well-differentiated thyroid cancer and nonmalignant thyroid conditions treated at our institutions (1996-2004). Methylation-specific polymerase chain reaction was performed, and results were compared with controls for these genes. Methylation status was then compared with patient variables, tumor factors, and outcome measures for patients with thyroid carcinoma and controls.
The study population comprised 32 patients with papillary thyroid carcinoma and 27 controls.
In our patients, all 5 genes were methylated more frequently in papillary thyroid carcinoma than in controls. NIS-L trended toward a more advanced stage at presentation. NIS-L methylation in cancer cells was not associated with methylation in adjacent benign tissue, unlike the other 4 genes. Neither age nor sex affected methylation status, and methylation status did not correlate with extent of the primary tumor or presence of nodal metastasis at diagnosis. Tumors recurred less frequently in patients with TSHR methylation than in patients with unmethylated TSHR promoter regions.
Promoter methylation may be a marker for malignancy in thyroid carcinoma. Furthermore, methylation status of tumors as determined by methylation-specific polymerase chain reaction may help in determining patient prognosis.
利用甲基化特异性聚合酶链反应确定编码促甲状腺激素受体(TSHR)、E-钙黏蛋白(ECAD)、钠碘同向转运蛋白(NIS-L)、共济失调毛细血管扩张症突变基因(ATM)和死亡相关蛋白激酶(DAPK)的基因启动子区域的甲基化状态,以及甲基化状态是否与甲状腺乳头状癌患者的患者变量、肿瘤因素或预后指标相关。
对在我们机构接受治疗的分化型甲状腺癌和非恶性甲状腺疾病患者(1996 - 2004年)进行数据库查询和回顾性病历审查。进行甲基化特异性聚合酶链反应,并将结果与这些基因的对照进行比较。然后将甲基化状态与甲状腺癌患者和对照的患者变量、肿瘤因素及预后指标进行比较。
研究人群包括32例甲状腺乳头状癌患者和27例对照。
在我们的患者中,甲状腺乳头状癌中所有5个基因的甲基化频率均高于对照。NIS-L在就诊时倾向于处于更晚期阶段。与其他4个基因不同,癌细胞中的NIS-L甲基化与相邻良性组织中的甲基化无关。年龄和性别均未影响甲基化状态,甲基化状态与诊断时原发肿瘤的范围或淋巴结转移的存在无关。TSHR甲基化的患者肿瘤复发频率低于TSHR启动子区域未甲基化的患者。
启动子甲基化可能是甲状腺癌恶性程度的一个标志物。此外,通过甲基化特异性聚合酶链反应确定的肿瘤甲基化状态可能有助于确定患者的预后。